Jacqueline Zummo Sells 22,598 Shares of Protara Therapeutics (NASDAQ:TARA) Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 22,598 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $5.26, for a total value of $118,865.48. Following the transaction, the insider directly owned 95,961 shares of the company’s stock, valued at approximately $504,754.86. This represents a 19.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA opened at $5.11 on Friday. Protara Therapeutics, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $7.82. The firm’s 50 day moving average price is $6.03 and its 200 day moving average price is $5.58. The stock has a market cap of $276.35 million, a price-to-earnings ratio of -3.87 and a beta of 1.50.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, equities analysts anticipate that Protara Therapeutics, Inc. will post -3.32 EPS for the current year.

Analysts Set New Price Targets

TARA has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a report on Tuesday, February 10th. JPMorgan Chase & Co. initiated coverage on Protara Therapeutics in a report on Wednesday, March 4th. They set an “overweight” rating and a $27.00 price target for the company. TD Cowen reiterated a “buy” rating on shares of Protara Therapeutics in a report on Tuesday, March 10th. Piper Sandler began coverage on Protara Therapeutics in a research report on Wednesday, January 7th. They set an “overweight” rating and a $24.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Institutional Trading of Protara Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. ADAR1 Capital Management LLC boosted its position in shares of Protara Therapeutics by 3,127.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock valued at $6,059,000 after purchasing an additional 1,101,576 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in Protara Therapeutics during the 4th quarter worth approximately $5,562,000. Janus Henderson Group PLC increased its position in Protara Therapeutics by 21.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock worth $27,379,000 after buying an additional 910,285 shares during the period. Integral Health Asset Management LLC boosted its holdings in shares of Protara Therapeutics by 60.7% in the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock valued at $11,992,000 after acquiring an additional 850,000 shares during the period. Finally, Maven Securities LTD acquired a new stake in shares of Protara Therapeutics in the fourth quarter valued at approximately $4,022,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.